Hamdan AlAwadhi, Muna Almutawa, Sara El Ouali, Zaher Koutoubi, Esat Memisoglu, Ahmad AlDuaij, Rajaie Namas
{"title":"治疗钢丝：用利尚单抗治疗克罗恩病和系统性红斑狼疮","authors":"Hamdan AlAwadhi, Muna Almutawa, Sara El Ouali, Zaher Koutoubi, Esat Memisoglu, Ahmad AlDuaij, Rajaie Namas","doi":"10.14309/crj.0000000000001830","DOIUrl":null,"url":null,"abstract":"<p><p>The coexistence of systemic lupus erythematosus (SLE) and Crohn disease (CD) is rare and presents significant diagnostic and therapeutic challenges due to overlapping clinical, radiologic, and histologic features. We present a 24-year-old woman with SLE, chronic immune thrombocytopenic purpura, and newly diagnosed CD treated with risankizumab, an interleukin-23 inhibitor approved for CD. She achieved complete clinical and radiologic remission of CD without SLE flares over 12 months. To the best of our knowledge, this represents the first documented case of risankizumab successfully used in a patient with SLE and CD. Further research is needed to assess the long-term safety and wider applicability of interleukin-23 inhibitors for this underserved patient population.</p>","PeriodicalId":7394,"journal":{"name":"ACG Case Reports Journal","volume":"12 9","pages":"e01830"},"PeriodicalIF":0.5000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417001/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Therapeutic Tightrope: Managing Coexisting Crohn Disease and Systemic Lupus Erythematosus With Risankizumab.\",\"authors\":\"Hamdan AlAwadhi, Muna Almutawa, Sara El Ouali, Zaher Koutoubi, Esat Memisoglu, Ahmad AlDuaij, Rajaie Namas\",\"doi\":\"10.14309/crj.0000000000001830\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The coexistence of systemic lupus erythematosus (SLE) and Crohn disease (CD) is rare and presents significant diagnostic and therapeutic challenges due to overlapping clinical, radiologic, and histologic features. We present a 24-year-old woman with SLE, chronic immune thrombocytopenic purpura, and newly diagnosed CD treated with risankizumab, an interleukin-23 inhibitor approved for CD. She achieved complete clinical and radiologic remission of CD without SLE flares over 12 months. To the best of our knowledge, this represents the first documented case of risankizumab successfully used in a patient with SLE and CD. Further research is needed to assess the long-term safety and wider applicability of interleukin-23 inhibitors for this underserved patient population.</p>\",\"PeriodicalId\":7394,\"journal\":{\"name\":\"ACG Case Reports Journal\",\"volume\":\"12 9\",\"pages\":\"e01830\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417001/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACG Case Reports Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14309/crj.0000000000001830\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACG Case Reports Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/crj.0000000000001830","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
A Therapeutic Tightrope: Managing Coexisting Crohn Disease and Systemic Lupus Erythematosus With Risankizumab.
The coexistence of systemic lupus erythematosus (SLE) and Crohn disease (CD) is rare and presents significant diagnostic and therapeutic challenges due to overlapping clinical, radiologic, and histologic features. We present a 24-year-old woman with SLE, chronic immune thrombocytopenic purpura, and newly diagnosed CD treated with risankizumab, an interleukin-23 inhibitor approved for CD. She achieved complete clinical and radiologic remission of CD without SLE flares over 12 months. To the best of our knowledge, this represents the first documented case of risankizumab successfully used in a patient with SLE and CD. Further research is needed to assess the long-term safety and wider applicability of interleukin-23 inhibitors for this underserved patient population.
期刊介绍：
ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
